Quarterly ResultMay 7, 2026, 07:08 AM
Amylyx Q1 Net Loss $(41.3)M; Cash $229.1M; Legal Settlement
AI Summary
Amylyx Pharmaceuticals reported a net loss of $41.3 million for Q1 2026, an increase from $35.9 million in Q1 2025. Despite the higher net loss, net loss per share improved to $(0.37) due to a significant increase in weighted-average shares outstanding. The company ended the quarter with $229.1 million in cash and cash equivalents. Additionally, Amylyx reached an agreement in principle to settle a class action lawsuit for $6.5 million, largely covered by insurance, while facing multiple ongoing derivative complaints.
Key Highlights
- Q1 2026 net loss was $(41.3) million, up from $(35.9) million in Q1 2025.
- Net loss per share improved to $(0.37) in Q1 2026 from $(0.42) in Q1 2025.
- Cash and cash equivalents totaled $229.1 million as of March 31, 2026.
- Total operating expenses increased to $43.8 million in Q1 2026 from $37.8 million in Q1 2025.
- Net cash used in operating activities was $(36.9) million, an improvement from $(39.8) million in Q1 2025.
- Amylyx agreed to settle a class action lawsuit for $6.5 million, largely covered by insurance.
- Research and development expenses rose to $27.6 million in Q1 2026 from $22.1 million in Q1 2025.
- Marketable securities decreased to $50.6 million as of March 31, 2026, from $90.3 million at December 31, 2025.
Price Impact
More from AMLX